Product Name: Aven Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, IF, IHC-P, WB
Applications: Aven antibody can be used for detection of Aven by Western blot at 1 μg/mL. Despite its predicted molecular weight, Aven often migrates at 55 kDa in SDS-PAGE. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: Aven antibody was raised against a 14 amino acid synthetic peptide from near the carboxy terminus of human Aven.The immunogen is located within the last 50 amino acids of Aven.
Host Species: Rabbit
Purification: Aven Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 548-66-3
Product: Drofenine (hydrochloride)
Buffer: Aven Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
Storage Conditions: Aven antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Aven Antibody: PDCD12, Cell death regulator Aven
Accession NO.: NP_065104
Protein Ino: 9966841
Official Symbol: AVEN
Geneid: 57099
Background: Aven Antibody: Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer. Aven is a recently discovered protein that blocks apoptosis induced by Apaf-1 and caspase-9. It is thought that Aven functions by binding to Bcl-xL, an antiapoptotic member of the Bcl-2 family, and to Apaf-1, possibly interfering with the ability of Apaf-1 to self-associate, suggesting that Aven impedes Apaf-1-mediated caspase activation. Higher levels of Aven mRNA are seen in patients with acute leukemia than in control patients, suggesting that Aven may be useful as a prognostic indicator in leukemia patients.
PubMed ID:http://aac.asm.org/content/53/8/3256.abstract
